PlatinumÁ¦·Î Ç×¾Ï Ä¡·áÇÑ ÁøÇ༺ ºñ¼Ò¼¼Æ÷Æó¾ÏÁ¾ ȯÀÚ¿¡¼ HER-2/neu, ERCC1°ú GST-pi¿¡ ´ëÇÑ ¿¬±¸
An Analysis of HER-2/neu, ERCC1, and GST-pi in Advanced Non-Small Cell Lung Cancer Patients Who are Treated with Platinum-based Chemotherapy
´ëÇѺ´¸®ÇÐȸÁö 2008³â 42±Ç 6È£ p.327 ~ p.334
¼°æÁø(Seo Kyung-Jin) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ º´¿øº´¸®Çб³½Ç
½Éº´¿ë(Shim Byoung-Yong) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±èÈƱ³(Kim Hoon-Kyo) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Á¤ÁöÇÑ(Jung Ji-Han) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ º´¿øº´¸®Çб³½Ç
À¯Áø¿µ(Yoo Jin-Young) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ º´¿øº´¸®Çб³½Ç
°¼®Áø(Kang Seok-Jin) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ º´¿øº´¸®Çб³½Ç
À̱³¿µ(Lee Kyo-Young) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ º´¿øº´¸®Çб³½Ç
Abstract
Background : Platinum-based chemotherapy has shown to be an effective first-line treatment for patients with advanced stage, unresectable non-small cell lung cancer (NSCLC). We evaluated the response rate to combination chemotherapy with cisplatin and taxane, and the significance of the HER-2/neu, ERCC1, and GST-pi status as predictive markers for the tumor response.
Methods : The HER-2/neu, ERCC1, and GST-pi status were analyzed in the biopsy specimens obtained from 35 patients with advanced stage NSCLC prior to cisplatin plus either paclitaxel or docetaxel chemotherapy.
Results : The response rate of the tumors to combination chemotherapy was 62.9% (22/35). HER-2/neu was amplified in 51.4% (18/35) of the tumors, and this was observed exclusively in patients with progressive disease (p=0.014). ERCC1 was overexpressed in 77.2% of the specimens (27/35), and this showed a tendency to correlate with the tumor response (p=0.057). GST-pi was detected in 85.7% of the specimens (30/35). Seventy-seven percent of the patients with a negative HER-2/neu and positive ERCC1 status showed a partial response, which was in contrast to only a 25% response rate for the patients with a positive HER-2/neu and negative ERCC1 status (p=0.006). The overall survival was prolonged in the patients without HER-2/neu amplification (15 vs 8.5 months, respectively, p=0.008). On multivariate analysis, the HER-2/neu status remained the significant predictor of survival (p=0.005).
Conclusions : A combination of the ERCC1, HER-2/neu status may define a subset of patients with the most favorable response to combination chemotherapy regimens for treating advanced NSCLC.
Å°¿öµå
Carcinoma, Non-small cell lung, Genes, HER-2, ERCC1 protein, human, Glutathione S-transferase pi, Cisplatin
KMID :
0357920080420060327
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
ÀÏÂ÷Ç×¾ÏÄ¡·áÁ¦·Î cisplatin°ú taxaneÀ» »ç¿ëÇß°í 62.9%ÀÇ ¹ÝÀÀ·üÀ» ³ªÅ¸³Â´Ù. ¼·Î ´Ù¸¥ ±âÀüÀ¸·Î cisplatin¿¡ °ü¿©ÇÏ´Â HER-2/neu, ERCC1, GST-pi »óŸ¦ ºÐ¼®ÇÑ °á°ú, HER-2/neu°¡ ¾àÁ¦³»¼º ¹× »ýÁ¸±â°£°ú À¯ÀÇÇÑ »ó°ü°ü°è¸¦ º¸¿´°í, ERCC1 ´Ü¹éÀº ¾àÁ¦³»¼º°ú À¯ÀÇ ¼öÁØ¿¡ ±ÙÁ¢ÇÏ´Â »ó°ü¼ºÀ» ³ªÅ¸³¿.; The overall survival was prolonged in the patients without HER-2/neu amplification.